Company profilePharmaceutical#68 of 1,318 in Pakistan5 DRAP alerts

Pulse Pharmaceuticals (Pvt.) Ltd.

Pharmaceutical company · 212 brands · 188 molecules

Ranked #10 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

212 registered products 57 pharmaceutical brands 188 distinct molecules 5 DRAP alerts

Company overview

212
registered products
57
pharmaceutical brands
188
distinct molecules
12
therapeutic classes
5
DRAP alerts

Pulse Pharmaceuticals (Pvt.) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 212 product registrations across 188 distinct molecules. It is the 68th largest registrant in Pakistan by product count, and ranks 10th of 311 in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord). Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Blood Glucose Lowering Drugs, Excluding Insulin. DRAP has issued 5 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Pulse

101 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) 3

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

100
ceilings with an approval date
5
not revised in 2+ years
2024
oldest approval year
20245
202583
202612
Longest without revision

Top molecules by brand count

Levofloxacin5 brands
Ceftriaxone5 brands
Atorvastatin5 brands
Paracetamol5 brands
Cefotaxime5 brands
Amlodipine5 brands
Lisinopril5 brands
Omeprazole4 brands
Cefixime4 brands

Therapeutic classes

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 9Blood Glucose Lowering Drugs, Excluding Insulin · 6Lipid Modifying Agents · 3Drugs For Constipation · 3Quinolone Antibacterials · 2Angiotensin-Ii Antagonists, Combinations · 2Antithrombotic Agents · 2Antiemetics & Antinauseants · 2Ace Inhibitor · 2Antianemic, Iron Preparations · 2Cardiac Care · 1Other Beta-Lactam, Cephalosporins & Penems · 1

Conditions treated

High Cholestrol · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official175 products · Rs 4.04 – Rs 13,339.3
Servaid2 products · Rs 138 – Rs 218
Median across source: Rs 334.57

Regulatory record

5 alerts in the DRAP feed we track.

35. Recall Alert – DTL Punjab Declared Substandard Drug Products.
2026-06-18
Safety Alert of Risk of severe itching after discontinuation of long-term use of Cetirizin
2026-02-09
130. Recall Alert – Drug Testing Laboratories, Punjab – Substandard products.
2026-01-14
109. Recall Alert (Class-I) – Zayzine Syrup (Batch # 25289)
2025-11-17
Recall Alert (Class-II) – Drug Products Declared substandard by Directorate of Drugs Contr
2025-09-15

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GETZ PHARMA PAKISTAN (PVT) LTD. holds 236 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAmitriptyline
BIO LABS (PVT) LTD. holds 104 molecules not in this portfolio
000 I.UAprepitantAremetherArtesunateAscorbic AcidAzathioprine
NABIQASIM INDUSTRIES (PVT) LTD. holds 163 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir

Get the full profile for Pulse

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.